COMMUNIQUÉS West-GlobeNewswire

Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)
30/01/2019
NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today [...]
Aino Health AB (publ): Aino Health signs partnership agreement with Uudenmaan Työterveys, (Nylands Arbetshälsa)
30/01/2019
30 January 2019 Aino Health and Uudenmaan Työterveys, (Nylands Arbetshälsa), have signed a partnership agreement regarding Aino's SaaS solution HealthManager and Aino's consulting services in preventive healthcare. The [...]
Kamada Appoints Senior Biopharmaceutical Executive Michal Ayalon, Ph.D., as Vice President of Research and Development
30/01/2019
REHOVOT, Israel, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today the appointment of Michal Ayalon, Ph.D., as Vice President of [...]
Mithra Announces Positive Top-line Results of Estelle® Phase III Oral Contraceptive Study in U.S/Canada
30/01/2019
Mithra Announces Positive Top-line Results of Estelle ® Phase III Oral Contraceptive Study in U.S/Canada Primary efficacy endpoint indicates excellent contraceptive efficacy, with a Pearl Index (PI) of 2.41 1 per 100 [...]
Emerald Health Therapeutics Announces Discharge of Litigation
30/01/2019
VANCOUVER, British Columbia, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) announced today that its wholly-owned subsidiary, Verdélite Sciences Inc. (“Verdélite [...]
Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis
30/01/2019
MIST-1 study met primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, high tolerability; Study further validates OpteJet™ platform delivery technology Company to host [...]
Trevena Announces $10 Million Registered Direct Offering of Common Stock
30/01/2019
CHESTERBROOK, Pa., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (the “Company”) today announced that it entered into securities purchase agreements with two healthcare-focused institutional investors, [...]
Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy
30/01/2019
Topline results anticipated in 2Q 2019 NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of [...]
Terveystalo Plc: Proposals of the Shareholders Nomination Board to the Annual General Meeting 2019
30/01/2019
Terveystalo Plc Stock Exchange Release 30 January 2019 at 13:00 EET The Shareholders' Nomination Board of Terveystalo has submitted its proposal on the Board of Directors to the Annual General Meeting 2019. Proposal on [...]
Release date of annual report 2018 for ALK and audio cast
30/01/2019
On Thursday, 7 February 2019, ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) releases its annual report for 2018. ALK will host a meeting for analysts and institutional investors that day at 12.30 p.m. (CET) at which [...]
Enzymatica AB: First patients included in large placebo-controlled multicentre study on ColdZyme
30/01/2019
Press release 30 January 2019 First patients included in large placebo-controlled multicentre study on ColdZyme Enzymatica has initiated a prospective double-blind, placebo-controlled multicentre study to evaluate the [...]
Changes to the Nomination Committee for Immunicum AB (publ)
30/01/2019
Press Release 30 January 2019 Changes to the Nomination Committee for Immunicum AB (publ) Immunicum AB (publ) (the "Company" or "Immunicum") announced the composition of the Nomination Committee on 19 October 2018. As a [...]
Curetis’ Unyvero Application Cartridges Receive Regulatory Approvals in Malaysia and Thailand
30/01/2019
HPN Cartridge approved in Malaysia; HPN, BCU Cartridges approved in Thailand Further commercial roll-out of Unyvero in ASEAN region by partner Acumen Research Laboratories facilitated Near-term Chinese NMPA submission [...]
Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)
30/01/2019
Orphazyme A/S Company announcement No. 01/2019 Company Registration No. 32266355 Primary endpoint shows 74% reduction in disease progression after 12 months compared to placebo control (p-value =0.0506) Biomarker [...]
Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
30/01/2019
Full year net sales up 5% (cc[1], +6% USD) driven by strong performance of growth drivers: Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0 billion (+102% cc) Oncology BU [...]
En 2018, Novartis a enregistré une forte croissance de ses ventes, avec une expansion de sa marge core, développé des plates-formes leaders de traitements de pointe, et recentré l'entreprise
30/01/2019
Hausse du chiffre d'affaires net de 5% (tcc[1], +6% USD) en 2018, soutenue par l'excellente performance des moteurs de croissance : Pharmaceuticals: cette unité opérationnelle a progressé de 7% (tcc), impulsée par [...]
Bone Therapeutics SA: Information on the total number of voting rights and shares
30/01/2019
Regulated information Gosselies, Belgium, 30 January 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone [...]
Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions
30/01/2019
Information réglementée Gosselies, Belgique, le 30 janvier 2019, 07h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d’importants besoins [...]
ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring
29/01/2019
SINGAPORE, Jan. 29, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets, today announced [...]

Pages